Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for generalized AChR-antibody positive myasthenia gravis
2020-005619-35Phase 3Active
- Sponsor
- Policlinico Gemelli
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of rituximab in myasthenia gravis (MG), sponsored by Policlinico Gemelli. Primary endpoint: Change from baseline in Quantitative Myasthenia Gravis Score at week 12. Started Aug 2021; status: active.
02
Drugs
rituximab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2020-005619-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005619-35.